Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
In elderly and senile patients, chronic kidney disease (CKD) is not always diagnosed promptly and is often attributed to age-related changes in kidney function. Estimated glomerular filtration rate (eGFR) does not allow one to determine the contribution of pathology to eGFR, as this indicator also includes age-related decline in kidney function. The aim of the study was to assess the contribution of kidney pathology to the estimated glomerular filtration rate and its prognostic value in elderly and senile patients.
472 elderly and senile age patients (241 women and 231 men, mean age 69.6±7.3 years) with stable cardiovascular diseases were examined. CKD was observed in 302 (63.9 %) elderly and senile patients. Estimated glomerular filtration rate (eGFR) was determined using the CKD-EPI equation (modified 2011). The contribution of kidney pathology (CKP) to eGFR was calculated by the difference between the “real” eGFR (calculated using the CKD-EPI, 2011 formula based on the “real” serum creatinine) and the predicted eGFR for a given age and sex (patent No. RU 2723748 C1). The follow-up period was 12 months. The primary endpoint was overall mortality.
The CKP in eGFR in elderly and senile patients was 26.3 (14.9;35.7) %, increasing with the severity of CKD. The CKP in eGFR in elderly and senile patients with CKD did not differ depending on gender and age (p>0.05). The modified Charlson comorbidity index was higher in patients with CKD with CKP in eGFR more than 43.3 % compared to patients with The CKP in eGFR less than 43.3 (p = 0.004). The CKP in eGFR more than 43.3 % was associated with a 1-year risk of death in patients with CKD (OR 4.7; 95 % CI 1.99–10.9; p<0.0001). When assessing the prognostic value of CKP in eGFR, regardless of the CKD it was found that an increase CKP in eGFR more than 17.9 % was associated with a 1-year risk of death in elderly and senile patients with stable cardiovascular diseases (OR 2.47; 95 % CI 1.31–4.67; p=0.004).
The contribution of kidney pathology in eGFR in elderly and senile patients with CKD and stable cardiovascular comorbidity increases with the severity of CKD and does not depend on gender and age. In elderly and senile patients with stable cardiovascular diseases, the CKP in eGFR has prognostic advantages when assessing annual mortality compared to eGFR assessment using the CKD EPI formula (2011).
